Eli Lilly And Company ((LLY)), Rigel Pharmaceuticals ((RIGL)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a recent update, Eli Lilly and Company, in collaboration with Rigel Pharmaceuticals, is conducting an adaptive Phase 2a/2b study titled ‘An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis.’ The study aims to assess the efficacy and safety of the drug LY3871801 in treating adults with active moderately-to-severe rheumatoid arthritis, a condition that significantly impacts quality of life.
The intervention being tested is LY3871801, an orally administered drug, compared against a placebo. The study involves multiple phases, with participants receiving different doses of LY3871801 to evaluate its effectiveness and safety profile.
This interventional study employs a randomized, parallel assignment model with double masking to ensure unbiased results. The primary purpose is treatment, focusing on evaluating the therapeutic potential of LY3871801.
The study began on May 23, 2023, and is currently recruiting participants. The last update was submitted on July 22, 2025, indicating ongoing progress. These dates are crucial as they reflect the study’s timeline and current status.
The outcome of this study could significantly influence Eli Lilly’s and Rigel Pharmaceuticals’ stock performance, as positive results might boost investor confidence and market share, especially in the competitive rheumatoid arthritis treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.